{
    "nct_id": "NCT06572800",
    "official_title": "Use of DiviTum-TKa as a Biomarker Assay for CDK4/6 Inhibitor Medication Compliance and Drug-Drug Interaction Assessment in ER/PR Positive Metastatic Breast Cancer",
    "inclusion_criteria": "* Participants must have histologically confirmed metastatic ER-positive (> 10%), PR-positive or PR-negative, and HER2-negative (0 by immunohistochemistry [IHC] or if +1 or +2 by IHC, not amplified by fluorescence in situ hybridization [FISH]) breast cancer; ER positivity, PR positivity, and HER2 negativity as per the 2018 joint American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.\n* Participants must be starting CDK4/6 inhibitor and endocrine therapy as part of first-line therapy per standard of care and be previously CDK4/6 inhibitor-naïve.\n* Participants must be enrolled prior to starting CDK4/6 inhibitor therapy.\n* Participants must be ≥ 18 years of age.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status < 3.\n* Willing and able to provide written informed consent for the trial.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants without evidence of metastatic disease prior to registration.\n* Participants with prior use of CDK4/6 inhibitor therapy.\n* Participants who are unable to provide informed consent for the trial.",
    "miscellaneous_criteria": ""
}